CEL-SCI (FRA:LSR) Total Liabilities: €9.37 Mil (As of Mar. 2026)


FRA:LSR CEL-SCI Corp FRA:LSR
23 GF Score
Price €0.76
! 2 Warning Signs
View Full Analysis

What is CEL-SCI Total Liabilities?

CEL-SCI FRA:LSR -9.52% 23 Total Liabilities is €9.37 Mil as of Mar. 2026. GuruFocus rates FRA:LSR with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

CEL-SCI's Total Liabilities for the quarter that ended in Mar. 2026 was €9.37 Mil.

CEL-SCI's quarterly Total Liabilities declined from Sep. 2025 (€10.39 Mil) to Dec. 2025 (€10.04 Mil) and declined from Dec. 2025 (€10.04 Mil) to Mar. 2026 (€9.37 Mil).

CEL-SCI's annual Total Liabilities declined from Sep. 2023 (€16.22 Mil) to Sep. 2024 (€12.73 Mil) and declined from Sep. 2024 (€12.73 Mil) to Sep. 2025 (€10.39 Mil).

CEL-SCI Total Liabilities Historical Data

* Premium members only.

The historical data trend for CEL-SCI's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CEL-SCI Total Liabilities Chart

CEL-SCI Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.44 18.54 16.22 12.73 10.39

CEL-SCI Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.77 11.54 10.39 10.04 9.37
FRA:LSR
23GF Score
CEL-SCI Corp FRA:LSR
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CEL-SCI Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CEL-SCI's Total Liabilities for the fiscal year that ended in Sep. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.372+(5.915+0.107
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=10.39

Total Liabilities=Total Assets (A: Sep. 2025 )-Total Equity (A: Sep. 2025 )
=23.989-13.595
=10.39

CEL-SCI's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.159+(5.103+0.109
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=9.37

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=15.317-5.947
=9.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €9.37 Mil mean?
CEL-SCI (FRA:LSR) has a Total Liabilities of €9.37 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CEL-SCI and its competitors.
Is CEL-SCI's Total Liabilities too high?
CEL-SCI's current Total Liabilities is €9.37 Mil. Overall, CEL-SCI has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does CEL-SCI's Total Liabilities compare to TRAW and QNCX?
CEL-SCI's Total Liabilities of €9.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CEL-SCI and its competitors. CEL-SCI's current Total Liabilities is €9.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CEL-SCI stock overvalued right now?
CEL-SCI (FRA:LSR) has a current Total Liabilities of €9.37 Mil. The current Total Liabilities is €9.37 Mil. CEL-SCI's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For CEL-SCI (FRA:LSR), the current Total Liabilities is €9.37 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CEL-SCI Business Description

Other Exchanges CVM:USA
Address 8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
23GF Score

Get the complete analysis for FRA:LSR

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.76
Price